Management of cardiac sarcoidosis in the United States: A Delphi study

Chest

Volumn 141, Issue 1, 2012, Pages 154-162

  Hamzeh, Nabeel Y ^a   Wamboldt, Frederick S ^a   Weinberger, Howard D ^a  

^a DEPARTMENT OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; FLUORODEOXYGLUCOSE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TUMOR NECROSIS FACTOR ANTIBODY;

ARTICLE; CARDIAC SARCOIDOSIS; CONSENSUS DEVELOPMENT; COOPERATION; DEFIBRILLATION; DELPHI STUDY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART DISEASE; HOLTER MONITORING; HUMAN; MEDICAL DECISION MAKING; MEDICAL EXPERT; MEDICAL HISTORY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SARCOIDOSIS; SIGNAL AVERAGED ELECTROCARDIOGRAPHY; TREATMENT DURATION; UNITED STATES;

EID: 84855428535     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-0263     Document Type: Article

References (26)

1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS), and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160(2):736-755.
2. Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest. 1993;103(1):253-258. (Pubitemid 23027268)
3. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58(6):1204-1211. (Pubitemid 9092005)
4. Doughan AR, Williams BR. Cardiac sarcoidosis. Heart. 2006;92(2):282-288. (Pubitemid 43131983)
5. Gideon NM, Mannino DM. Sarcoidosis mortality in the United States 1979-1991: an analysis of multiple-cause mortality data. Am J Med. 1996;100(4):423-427. (Pubitemid 26115197)
6. Hiraga Kyamhea H. Guideline for Diagnosis of Cardiac Sarcoidosis: Study Report on Diffuse Pulmonary Disease From the Japanese Ministry of Health and Welfare. Tokyo, Japan: Japanese Ministry of Health and Welfare; 1993:23-24.
7. Sharma OP. Myocardial sarcoidosis. A wolf in sheep's clothing. Chest. 1994;106(4):988-990. (Pubitemid 24309526)
8. Judson MA. Cardiac sarcoidosis: there is no instant replay. Chest. 2005;128(1):3-6. (Pubitemid 40994442)
9. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs. 2000;32(4):1008-1015.
10. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ. 1995;311(7001):376-380.
11. Mehta D, Lubitz SA, Frankel Z, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 2008:133(6):1426-1435. (Pubitemid 351893001)
12. Chapelon-Abric C, de Zuttere D, Duhaut P, et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore). 2004;83(6):315-334. (Pubitemid 39541109)
13. Okayama K, Kurata C, Tawarahara K, Wakabayashi Y, Chida K, Sato A. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest. 1995;107(2):330-334.
14. Suzuki T, Kanda T, Kubota S, Imai S, Murata K. Holter monitoring as a noninvasive indicator of cardiac involvement in sarcoidosis. Chest. 1994;106(4):1021-1024. (Pubitemid 24309534)
15. Schuller JL, Lowery CM, Zipse M, et al. Diagnostic utility of signal-averaged electrocardiography for detection of car diac sarcoidosis. Ann Noninvasive Electrocardiol. 2011;16(1):70-76.
16. Dhôte R, Vignaux O, Blanche P, et al. Value of MRI for the diagnosis of cardiac involvement in sarcoidosis [in French]. Rev Med Interne. 2003;24(3):151-157. (Pubitemid 36363008)
17. 18F-FDG PET scan as follow-up tool for sarcoidosis with symptomatic cardiac conduction disturbances requiring a pacemaker. Thorax. 2007;62(6):560.
18. 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging. 2008;35(5):933-941.
19. 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med. 2004;45(12):1989-1998.
20. Smedema J-P, Snoep G, van Kroonenburgh MPG, et al. The additional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis. Chest. 2005;128(3):1629-1637. (Pubitemid 41324457)
21. Tadamura E, Yamamuro M, Kubo S, et al. Effectiveness of delayed enhanced MRI for identification of cardiac sarcoidosis: comparison with radionuclide imaging. AJR Am J Roentgenol. 2005;185(1):110-115.
22. Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18F-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol. 2009;16(5):801-810.
23. Smedema JP, Snoep G, van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45(10):1683-1690. (Pubitemid 40704507)
24. Yazaki Y, Isobe M, Hiroe M, et al. Central Japan Heart Study Group. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88(9):1006-1010. (Pubitemid 33042612)
25. Yamagishi H, Shirai N, Takagi M, et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med. 2003;44(7):1030-1036. (Pubitemid 39663376)
26. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008;117(21):2820-2840. (Pubitemid 351770463)